Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924244 | 0.89 | SCN5A (0.47) | SCN5ANOTUMPIM1SRCGSK3A | |
| SCHEMBL10203097 | 0.82 | SCN5A (0.61) | SCN5ANOTUMPARP10CHEK1 | |
| SCHEMBL3435779 | 0.78 | SCN5A (0.48) | SCN5ANOTUMPARP10CHEK1 | |
| SCHEMBL18632511 | 0.74 | LTK (0.55) | SCN5ANOTUMPIM1LRRK2CHEK1 | |
| SCHEMBL18632513 | 0.71 | SCN5A (0.49) | SCN5ANOTUMLRRK2CHEK1 | |
| SCHEMBL18632535 | 0.71 | SCN5A (0.62) | SCN5ANOTUMPIM1LRRK2CHEK1 | |
| SCHEMBL18632530 | 0.71 | SCN5A (0.62) | SCN5ANOTUMPIM1LRRK2CHEK1 | |
| SCHEMBL18632537 | 0.70 | SCN5A (0.48) | SCN5ANOTUMPIM1LRRK2CHEK1 | |
| SCHEMBL18632536 | 0.70 | SCN5A (0.51) | SCN5ANOTUMGSK3ACHEK1 | |
| SCHEMBL20772418 | 0.70 | CHEK1 (0.46) | SCN5ANOTUMCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081323-A1 | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | OAT, XDH, MAPT | SCN5A 1311/4885NOTUM 541/4885PIM1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.